Trial Profile

Study on the Pharmacokinetic Effects of Single-centered, Open, Single-arm, Fixed-sequence Itraconazole on SHR0302 Tablets in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Itraconazole (Primary) ; Ivarmacitinib (Primary)
Indications Rheumatoid arthritis
Focus Pharmacokinetics
Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

02 Apr 2023 Results(n=28 from Two Phase I, open-label, fixed-sequence drug interactions studies) assessing the effects of a strong CYP3A4 inducer, rifampin, and a strong CYP3A4 inhibitor, itraconazole, on the pharmacokinetics of SHR0302 in healthy subjects published in the British Journal of Clinical Pharmacology
21 Dec 2022 Status changed from active, no longer recruiting to completed.
08 Jul 2022 Status changed from not yet recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com